The estimated Net Worth of Equity Opportunities 17, Ll... is at least $106 Milion dollars as of 17 July 2023. Equity Ll owns over 333,333 units of Savara Inc stock worth over $105,715,860 and over the last few years Equity sold SVRA stock worth over $0.
Equity has made over 1 trades of the Savara Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Equity bought 333,333 units of SVRA stock worth $999,999 on 17 July 2023.
The largest trade Equity's ever made was buying 333,333 units of Savara Inc stock on 17 July 2023 worth over $999,999. On average, Equity trades about 333,333 units every 0 days since 2023. As of 17 July 2023 Equity still owns at least 24,471,264 units of Savara Inc stock.
You can see the complete history of Equity Ll stock trades at the bottom of the page.
Over the last 8 years, insiders at Savara Inc have traded over $2,203,958 worth of Savara Inc stock and bought 6,103,761 units worth $15,290,245 . The most active insiders traders include Forest Baskett, Scott D Sandell a Anthony A. Jr. Florence. On average, Savara Inc executives and independent directors trade stock every 29 days with the average trade being worth of $348,922. The most recent stock trade was executed by Matthew Pauls on 28 December 2023, trading 84,000 units of SVRA stock currently worth $395,640.
savara pharmaceuticals is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions. the company’s lead product, aerovanc is the first dry powder inhaled antibiotic for the treatment of methicillin-resistant staphylococcus aureus (mrsa) infection in patients with cystic fibrosis (cf). for more information, please see savara’s website at www.savarapharma.com or www.aerovanc.com
Savara Inc executives and other stock owners filed with the SEC include: